» Articles » PMID: 21911051

Bu-Fei Yi-Shen Granule Combined with Acupoint Sticking Therapy in Patients with Stable Chronic Obstructive Pulmonary Disease: a Randomized, Double-blind, Double-dummy, Active-controlled, 4-center Study

Overview
Date 2011 Sep 14
PMID 21911051
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Ethnopharmacological Relevance: Bu-Fei Yi-Shen granule combined with acupoint sticking therapy has been used in the patients with stable chronic obstructive pulmonary disease (COPD) as major traditional interventions for the treatment of the disease.

Aim Of The Study: The objective of this study was to evaluate the efficacy and safety of traditional Chinese herbal medicine, the Bu-Fei Yi-Shen granule combined with acupoint sticking therapy in patients with stable COPD.

Methods: A 4-center, double-blinded, double-dummy and randomized controlled method was conducted. 244 patients who were divided into the trial group (n=122, treated with Bu-Fei Yi-Shen granule combined with Shu-Fei Tie acupoint sticking therapy and oral placebo sustained-release theophylline) and the control group (n=122, treated with oral sustained-release theophylline and placebo Bu-Fei Yi-Shen granule combined with placebo Shu-Fei Tie acupoint sticking therapy). The frequency and duration of acute exacerbation, lung function, clinical symptoms, six-minute walking distance, dyspnea grade and quality of life were observed during the 4-month treatment period, and for a further 6 months follow-up.

Results: Two hundred and twenty one patients fully completed the study, intent-to-treat (ITT) population was 234 and per-protocol (PP) population was 221. After treatment for 4 months and follow-up for 6 months, there were differences between the experimental and control group in frequency of acute exacerbation (ITT: P=0.007, P=0.013; PP: P=0.045, P=0.046); duration of acute exacerbation (ITT: P=0.030, P=0.005; PP: P=0.048, P=0.006); scores of symptoms (ITT: P=0.000, P=0.000; PP: P=0.000, P=0.000); six-minute walking distance (ITT: P=0.002, P=0.001; PP: P=0.002, P=0.001); dyspnea grade (ITT: P=0.014, P=0.009; PP: P=0.018, P=0.012); physiological aspects (ITT: P=0.003, P=0.000; PP: P=0.001, P=0.000); psychological aspects (ITT: P=0.007, P=0.001; PP: P=0.001, P=0.000) and environment aspects (ITT: P=0.003, P=0.000; PP: P=0.001, P=0.000) of the WHOQOL-BREF questionnaire. There were no differences between the experimental and control group in FVC, FEV1 and FEV1% and adverse events.

Conclusions: Bu-Fei Yi-Shen granule combined with acupoint sticking therapy showed beneficial effects for patients with stable COPD in the measured parameters over the 4-month treatment period and 6 months follow-up, with no relevant between-group differences in adverse events.

Citing Articles

Effectiveness of Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Disease Therapy: Focusing on Traditional Medical Practices.

Tonga K, Oliver B J Clin Med. 2023; 12(14).

PMID: 37510930 PMC: 10381859. DOI: 10.3390/jcm12144815.


Effective Component Compatibility of Bufei Yishen Formula III Which Regulates the Mucus Hypersecretion of COPD Rats via the miR-146a-5p/EGFR/MEK/ERK Pathway.

Ma J, Liu X, Wei Y, Lu R, Xu K, Tian Y Evid Based Complement Alternat Med. 2023; 2022:9423435.

PMID: 36619199 PMC: 9812609. DOI: 10.1155/2022/9423435.


Chemical Identification and Antioxidant Screening of Bufei Yishen Formula using an Offline DPPH Ultrahigh-Performance Liquid Chromatography Q-Extractive Orbitrap MS/MS.

Wu J, Cai B, Zhang A, Zhao P, Du Y, Liu X Int J Anal Chem. 2022; 2022:1423801.

PMID: 36284795 PMC: 9588378. DOI: 10.1155/2022/1423801.


The Beneficial Role of Auricular Point Pressure in Insomnia and Anxiety in Isolated COVID-19 Patients.

Luo Y, Ling C, Liu Y, Deng C, Waaga-Gasser A, Chen M Evid Based Complement Alternat Med. 2021; 2021:6611942.

PMID: 34306148 PMC: 8282373. DOI: 10.1155/2021/6611942.


Efficacy and safety of Jia Wei Bushen Yiqi formulas as an adjunct therapy to systemic glucocorticoids on acute exacerbation of COPD: study protocol for a randomized, double-blinded, multi-center, placebo-controlled clinical trial.

Kong Q, Mo S, Wang W, Tang Z, Wei Y, Du Y Trials. 2020; 21(1):760.

PMID: 32883322 PMC: 7468179. DOI: 10.1186/s13063-020-04669-5.